Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after 90Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0 Journal Article
| Authors: | Shady, W.; Kishore, S.; Gavane, S.; Do, R. K.; Osborne, J. R.; Ulaner, G. A.; Gonen, M.; Ziv, E.; Boas, F. E.; Sofocleous, C. T. |
| Article Title: | Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after 90Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0 |
| Abstract: | Purpose: To compare the performance of 4 metrics of metabolic response on FDG-PET/CT against RECIST 1.0 for determining response and predicting overall survival (OS) following 90Y resin microspheres radioembolization of colorectal liver metastases (CLM). Methods: We conducted an IRB-waived retrospective review of our radioembolization database to identify patients with unresectable CLM treated between December 2009 and December 2013. We included patients who had both PET/CT and contrast enhanced CT (CECT) available at baseline and on the first follow-up post-radioembolization. On baseline CECT up to five target tumors were chosen per patient according to RECIST 1.0. Four metrics of FDG-avidity (SUVmax, SUVpeak, metabolic tumor volume (MTV), and total lesion glycolysis (TLG)) on PET/CT were measured for the same target tumors. Using RECIST 1.0, patients were classified as no progression (partial response or stable disease) and progression. For each PET metric, a cut-off point of ≥30% decrease was chosen to define response. OS was calculated from the time of radioembolization using Kaplan-Meier methodology. The log-rank test was used for univariate analysis to identify predictors of OS. Results: The study enrolled 49 patients with 119 target tumors; a median of 2 (range: 1-5) tumors were selected per patient. Median OS was 12.7 months (95%CI: 7.2-16.7). Response by MTV (P = 0.035) and TLG (P = 0.044) reached statistical significance in predicting OS. Response by SUVmax (P = 0.21), SUVpeak (P = 0.20) or no progression by RECIST 1.0 (P = 0.44) did not predict OS. Conclusion: Metabolic response based on changes in MTV and TLG can predict OS post-radioembolization of CLM. © 2016, Elsevier Ireland Ltd. All rights reserved. |
| Keywords: | overall survival; pet/ct; colorectal liver metastases; radioembolization; recist 1.0 |
| Journal Title: | European Journal of Radiology |
| Volume: | 85 |
| Issue: | 6 |
| ISSN: | 0720-048X |
| Publisher: | Elsevier B.V |
| Date Published: | 2016-06-01 |
| Start Page: | 1224 |
| End Page: | 1231 |
| Language: | English |
| DOI: | 10.1016/j.ejrad.2016.03.029 |
| PROVIDER: | scopus |
| PUBMED: | 27161074 |
| PMCID: | PMC5675072 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 May 2016 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work